[News Viscovery]
Horn (NL) / Vienna (AT), 21 February 2022 Viscovery profiles outcomes to bronchodilator therapy
Together with Maud Koopman and her colleagues from our long term customer CIRO+, we published the article Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study in the International Journal of Chronic Obstructive Pulmonary Disease.
The ACTIVATE study is a randomized, double-blind and placebo-controlled study investigating the effects of aclidinium bromide / formoterol fumarate bronchodilator therapy on lung hyperinflation and physical exercise capabilities. The outcome data on lung function and physical exercises were clustered with Viscovery SOMine to find typical outcome profiles and assess the impact of bronchodilator therapy.
Find the full open access article at www.dovepress.com